Historical Valuation
Protara Therapeutics Inc (TARA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.68. The fair price of Protara Therapeutics Inc (TARA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：5.61
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Protara Therapeutics Inc (TARA) has a current Price-to-Book (P/B) ratio of 1.57. Compared to its 3-year average P/B ratio of 0.67 , the current P/B ratio is approximately 135.68% higher. Relative to its 5-year average P/B ratio of 0.59, the current P/B ratio is about 168.12% higher. Protara Therapeutics Inc (TARA) has a Forward Free Cash Flow (FCF) yield of approximately -16.92%. Compared to its 3-year average FCF yield of -77.71%, the current FCF yield is approximately -78.22% lower. Relative to its 5-year average FCF yield of -68.00% , the current FCF yield is about -75.11% lower.
P/B
Median3y
0.67
Median5y
0.59
FCF Yield
Median3y
-77.71
Median5y
-68.00
Competitors Valuation Multiple
AI Analysis for TARA
The average P/S ratio for TARA competitors is 0.27, providing a benchmark for relative valuation. Protara Therapeutics Inc Corp (TARA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TARA
1Y
3Y
5Y
Market capitalization of TARA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TARA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TARA currently overvalued or undervalued?
Protara Therapeutics Inc (TARA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.68. The fair price of Protara Therapeutics Inc (TARA) is between NaN to NaN according to relative valuation methord.
What is Protara Therapeutics Inc (TARA) fair value?
TARA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Protara Therapeutics Inc (TARA) is between NaN to NaN according to relative valuation methord.
How does TARA's valuation metrics compare to the industry average?
The average P/S ratio for TARA's competitors is 0.27, providing a benchmark for relative valuation. Protara Therapeutics Inc Corp (TARA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Protara Therapeutics Inc (TARA) as of Jan 09 2026?
As of Jan 09 2026, Protara Therapeutics Inc (TARA) has a P/B ratio of 1.57. This indicates that the market values TARA at 1.57 times its book value.
What is the current FCF Yield for Protara Therapeutics Inc (TARA) as of Jan 09 2026?
As of Jan 09 2026, Protara Therapeutics Inc (TARA) has a FCF Yield of -16.92%. This means that for every dollar of Protara Therapeutics Inc’s market capitalization, the company generates -16.92 cents in free cash flow.
What is the current Forward P/E ratio for Protara Therapeutics Inc (TARA) as of Jan 09 2026?
As of Jan 09 2026, Protara Therapeutics Inc (TARA) has a Forward P/E ratio of -3.78. This means the market is willing to pay $-3.78 for every dollar of Protara Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Protara Therapeutics Inc (TARA) as of Jan 09 2026?
As of Jan 09 2026, Protara Therapeutics Inc (TARA) has a Forward P/S ratio of 0.00. This means the market is valuing TARA at $0.00 for every dollar of expected revenue over the next 12 months.